$1.69
3.98%
Nasdaq, Sep 24, 04:26 pm EDT. Closed.
ISIN
US15673T1007
Symbol
IPSC

Century Therapeutics Inc Stock price

$1.69
-0.43 20.28% 1M
-0.55 24.55% 6M
+0.70 69.88% YTD
+1.21 248.81% 1Y
-0.41 19.52% 3Y
-21.34 92.66% 5Y
-21.14 92.60% 10Y
-21.14 92.60% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
-0.07 3.98%
ISIN
US15673T1007
Symbol
IPSC
Industry

Is Century Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$306.0m
Enterprise Value
$186.3m
Net debt
positive
Cash
$119.7m
Shares outstanding
180.6m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
71.1%
Return on Equity
-6.0%
ROCE
-36.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-86.8m
EBIT
$-99.1m
Net Income
$-109.8m
Free Cash Flow
$-88.1m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
-344.3%
EBIT
-204.3%
Net Income
-371.6%
Free Cash Flow
23.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
16.4%
Employees
78
Rev per Employee
$1.4m

Century Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Century Therapeutics Inc forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Century Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Century Therapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
38% 38%
-
- Research and Development Expense 79 79
28% 28%
-
-87 -87
344% 344%
-
- Depreciation and Amortization 12 12
6% 6%
-
EBIT (Operating Income) EBIT -99 -99
204% 204%
-
Net Profit -110 -110
372% 372%
-

In millions USD.

Don't miss a Thing! We will send you all news about Century Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Century Therapeutics Inc Stock News

Neutral
GlobeNewsWire
●
15 days ago
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors.
Neutral
GlobeNewsWire
●
about one month ago
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure fo...
Neutral
Business Wire
●
2 months ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--IHI Power Services Corp. (IPSC), a leading operator of power plants across the U.S., has a new name as it enters a new chapter. Effective today, IPSC officially becomes Kyuden Energy Partners Corporation, following the completion of its acquisition by Kyuden International Corporation (Kyuden International), a wholly owned subsidiary of Kyushu Electric Power...
More Century Therapeutics Inc News

Company Profile

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO Dr. Pfeiffenberger
Employees 78
Founded 2018
Website www.centurytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today